Abstract
BackgroundThis paper describes the multi-institutional prospective phase II clinical trial, SPARK: Stereotactic Prostate Adaptive Radiotherapy utilizing Kilovoltage Intrafraction Monitoring (KIM). KIM is a real-time image guided radiotherapy technology being developed and clinically pioneered for prostate cancer treatment in Australia. It has potential for widespread use for target radiotherapy treatment of cancers of the pelvis, thorax and abdomen.MethodsIn the SPARK trial we will measure the cancer targeting accuracy and patient outcomes for 48 prostate cancer patients who will be treated in five treatment sessions as opposed to the conventional 40 sessions. The reduced number of treatment sessions is enabled by the KIM’s increased cancer targeting accuracy.DiscussionReal-time imaging in radiotherapy has the potential to decrease the time taken during cancer treatment and reduce the imaging dose required. With the imaging being acquired during the treatment, and the analysis being automated, there is potential for improved throughput. The SPARK trial will be conducted under the auspices of the Trans-Tasman Radiation Oncology Group (TROG).Trial registrationThis trial was registered on ClinicalTrials.gov on 09 March 2015. The identifier is: NCT02397317
Highlights
This paper describes the multi-institutional prospective phase II clinical trial, SPARK: Stereotactic Prostate Adaptive Radiotherapy utilizing Kilovoltage Intrafraction Monitoring (KIM)
* Correspondence: paul.keall@sydney.edu.au 1Radiation Physics Laboratory, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia Full list of author information is available at the end of the article clinical outcome data for prostate cancer stereotactic body radiation therapy (SBRT) are encouraging and maturing: the recent results of a pooled analysis of 1100 patients demonstrated excellent clinical efficacy, with biochemical disease control rates of greater than 93% at five years, as well as low patient reported toxicity [2, 3]
There is a history of advances in radiotherapy technology improving cancer treatment outcomes
Summary
In the SPARK trial we will measure the cancer targeting accuracy and patient outcomes for 48 prostate cancer patients who will be treated in five treatment sessions as opposed to the conventional 40 sessions. The reduced number of treatment sessions is enabled by the KIM’s increased cancer targeting accuracy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
